Mariano Barbacid
Centro de Investigaciones Oncológicas (CNIO), Madrid, Spain
Mariano Barbacid got his Ph.D. in Madrid’s Universidad Complutense (1974) and trained as a postdoctoral fellow at the US National Cancer Institute (1974-78). In 1978, he started his own research group. His work led in 1982, to the isolation of the first human oncogene, HRAS, and the identification of the first mutation associated with the development of human cancer.
He is also credited with the isolation of the TRK oncogene. This discovery led the
Barbacid group to identify in 1991 the TRK family of tyrosine protein kinase receptors as the functional receptors for the NGF family of neurotrophins. Today, TRK oncogenes have become the paradigm of agnostic tumor therapies.
In 1988, he joined Bristol Myers-Squibb where he became Vice President, Oncology Drug Discovery. In 1998, he returned to Madrid to create and direct the Spanish National Cancer Research Center (CNIO) which in less than 10 years became one of the top cancer research centres in the World. In 2011, Barbacid stepped down as CNIO Director to focus on his long-standing interests in identifying therapeutic strategies against KRAS mutant tumors. Barbacid was inducted to the US National Academy of Sciences in 2012 and in 2014 he was elected Fellow of the Academy of the American Association for Cancer Research. His work has been recognized by several domestic and international.. In 2011, he received an Endowed Chair from the AXA Research Fund (Paris). To date, he has authored 327 publications, including 245 original research articles in journals with impact factor. Currently, Barbacid’s Hirsch “h” factor is 122
Mariano Barbacid got his Ph.D. in Madrid’s Universidad Complutense (1974) and trained as a postdoctoral fellow at the US National Cancer Institute (1974-78). In 1978, he started his own research group. His work led in 1982, to the isolation of the first human oncogene, HRAS, and the identification of the first mutation associated with the development of human cancer.
He is also credited with the isolation of the TRK oncogene. This discovery led the
Barbacid group to identify in 1991 the TRK family of tyrosine protein kinase receptors as the functional receptors for the NGF family of neurotrophins. Today, TRK oncogenes have become the paradigm of agnostic tumor therapies.
In 1988, he joined Bristol Myers-Squibb where he became Vice President, Oncology Drug Discovery. In 1998, he returned to Madrid to create and direct the Spanish National Cancer Research Center (CNIO) which in less than 10 years became one of the top cancer research centres in the World. In 2011, Barbacid stepped down as CNIO Director to focus on his long-standing interests in identifying therapeutic strategies against KRAS mutant tumors. Barbacid was inducted to the US National Academy of Sciences in 2012 and in 2014 he was elected Fellow of the Academy of the American Association for Cancer Research. His work has been recognized by several domestic and international.. In 2011, he received an Endowed Chair from the AXA Research Fund (Paris). To date, he has authored 327 publications, including 245 original research articles in journals with impact factor. Currently, Barbacid’s Hirsch “h” factor is 122
